Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Fineline Cube Apr 20, 2026
Company Drug

BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial

Fineline Cube Jul 31, 2024

Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...

Company

Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak

Fineline Cube Jul 31, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...

Company

Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises

Fineline Cube Jul 31, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...

Company Drug

FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab

Fineline Cube Jul 31, 2024

US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...

Company Deals

National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China

Fineline Cube Jul 31, 2024

The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...

Policy / Regulatory

China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System

Fineline Cube Jul 31, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...

Company Deals

Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline

Fineline Cube Jul 31, 2024

Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful...

Policy / Regulatory

China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs

Fineline Cube Jul 31, 2024

In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Receives European Commission Approval

Fineline Cube Jul 31, 2024

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that its biosimilar version of Roche’s Avastin, Avzivi...

Company Drug

Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals

Fineline Cube Jul 31, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...

Company Medical Device

MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod

Fineline Cube Jul 31, 2024

Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Deals

Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility

Fineline Cube Jul 31, 2024

Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...

Company

Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

Fineline Cube Jul 31, 2024

Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...

Company Drug

Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA

Fineline Cube Jul 31, 2024

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...

Policy / Regulatory

China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies

Fineline Cube Jul 31, 2024

The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...

Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Company Drug

Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment

Fineline Cube Jul 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...

Posts pagination

1 … 309 310 311 … 654

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
  • Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.